Is PURR or TARA more profitable?

Protara Therapeutics' return on equity of -38.70% beat Hyperliquid Strategies' return on equity. Company Net Margins Return on Equity Return on Assets Hyperliquid Strategies N/A -56.04% -52.22% Protara Therapeutics N/A -38.70% -36.02%

Which has preferable earnings & valuation, SANA or TARA?

Sana Biotechnology is trading at a lower price-to-earnings ratio than Protara Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Sana Biotechnology N/A N/A -$244.17M -$0.93 N/A Protara Therapeutics N/A N/A -$57.44M -$1.34 N/A

Is SANA or TARA more profitable?

Protara Therapeutics' return on equity of -38.70% beat Sana Biotechnology's return on equity. Company Net Margins Return on Equity Return on Assets Sana Biotechnology N/A -108.01% -40.68% Protara Therapeutics N/A -38.70% -36.02%

Protara Therapeutics (TARA) Competitors

$3.95 +0.03 (+0.74%)

As of 10:52 AM Eastern

Compare

TARA vs. PURR, PHAR, SANA, TBPH, and ABUS

Should you buy Protara Therapeutics stock or one of its competitors? MarketBeat compares Protara Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Protara Therapeutics include Hyperliquid Strategies (PURR), Pharming Group (PHAR), Sana Biotechnology (SANA), Theravance Biopharma (TBPH), and Arbutus Biopharma (ABUS).

How does Protara Therapeutics compare to Hyperliquid Strategies?

Hyperliquid Strategies (NASDAQ:PURR) and Protara Therapeutics (NASDAQ:TARA) are related small-cap companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, dividends, risk, institutional ownership, valuation, analyst recommendations, earnings and media sentiment.

Hyperliquid Strategies presently has a consensus price target of $12.72, suggesting a potential upside of 100.39%. Protara Therapeutics has a consensus price target of $26.25, suggesting a potential upside of 572.90%. Given Protara Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Protara Therapeutics is more favorable than Hyperliquid Strategies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hyperliquid Strategies	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Protara Therapeutics	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75

9.5% of Hyperliquid Strategies shares are held by institutional investors. Comparatively, 38.1% of Protara Therapeutics shares are held by institutional investors. 8.5% of Hyperliquid Strategies shares are held by insiders. Comparatively, 7.6% of Protara Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Protara Therapeutics' return on equity of -38.70% beat Hyperliquid Strategies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Hyperliquid Strategies	N/A	-56.04%	-52.22%
Protara Therapeutics	N/A	-38.70%	-36.02%

Hyperliquid Strategies has a beta of 1.71, meaning that its stock price is 71% more volatile than the broader market. Comparatively, Protara Therapeutics has a beta of 1.48, meaning that its stock price is 48% more volatile than the broader market.

Hyperliquid Strategies has higher revenue and earnings than Protara Therapeutics. Protara Therapeutics is trading at a lower price-to-earnings ratio than Hyperliquid Strategies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hyperliquid Strategies	$1M	916.68	-$16.01M	-$7.37	N/A
Protara Therapeutics	N/A	N/A	-$57.44M	-$1.34	N/A

In the previous week, Hyperliquid Strategies had 4 more articles in the media than Protara Therapeutics. MarketBeat recorded 4 mentions for Hyperliquid Strategies and 0 mentions for Protara Therapeutics. Hyperliquid Strategies' average media sentiment score of 0.26 beat Protara Therapeutics' score of 0.00 indicating that Hyperliquid Strategies is being referred to more favorably in the media.

Company	Overall Sentiment
Hyperliquid Strategies	Neutral
Protara Therapeutics	Neutral

Summary

Hyperliquid Strategies and Protara Therapeutics tied by winning 7 of the 14 factors compared between the two stocks.

How does Protara Therapeutics compare to Pharming Group?

Protara Therapeutics (NASDAQ:TARA) and Pharming Group (NASDAQ:PHAR) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, earnings, risk, media sentiment, profitability, dividends, analyst recommendations and valuation.

Protara Therapeutics presently has a consensus target price of $26.25, indicating a potential upside of 572.90%. Pharming Group has a consensus target price of $38.33, indicating a potential upside of 282.19%. Given Protara Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Protara Therapeutics is more favorable than Pharming Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Protara Therapeutics	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75
Pharming Group	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Pharming Group has a net margin of 2.51% compared to Protara Therapeutics' net margin of 0.00%. Pharming Group's return on equity of 3.40% beat Protara Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Protara Therapeutics	N/A	-38.70%	-36.02%
Pharming Group	2.51%	3.40%	1.88%

Pharming Group has higher revenue and earnings than Protara Therapeutics. Protara Therapeutics is trading at a lower price-to-earnings ratio than Pharming Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Protara Therapeutics	N/A	N/A	-$57.44M	-$1.34	N/A
Pharming Group	$376.13M	1.89	$2.85M	$0.12	83.58

In the previous week, Pharming Group had 20 more articles in the media than Protara Therapeutics. MarketBeat recorded 20 mentions for Pharming Group and 0 mentions for Protara Therapeutics. Protara Therapeutics' average media sentiment score of 0.00 beat Pharming Group's score of -0.25 indicating that Protara Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Protara Therapeutics	Neutral
Pharming Group	Neutral

Protara Therapeutics has a beta of 1.48, meaning that its share price is 48% more volatile than the broader market. Comparatively, Pharming Group has a beta of -0.01, meaning that its share price is 101% less volatile than the broader market.

38.1% of Protara Therapeutics shares are owned by institutional investors. Comparatively, 0.0% of Pharming Group shares are owned by institutional investors. 7.6% of Protara Therapeutics shares are owned by company insiders. Comparatively, 2.1% of Pharming Group shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Pharming Group beats Protara Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Protara Therapeutics compare to Sana Biotechnology?

Sana Biotechnology (NASDAQ:SANA) and Protara Therapeutics (NASDAQ:TARA) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, risk, institutional ownership, profitability, earnings, dividends, media sentiment and valuation.

Sana Biotechnology is trading at a lower price-to-earnings ratio than Protara Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sana Biotechnology	N/A	N/A	-$244.17M	-$0.93	N/A
Protara Therapeutics	N/A	N/A	-$57.44M	-$1.34	N/A

Protara Therapeutics' return on equity of -38.70% beat Sana Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sana Biotechnology	N/A	-108.01%	-40.68%
Protara Therapeutics	N/A	-38.70%	-36.02%

Sana Biotechnology has a beta of 2.13, suggesting that its stock price is 113% more volatile than the broader market. Comparatively, Protara Therapeutics has a beta of 1.48, suggesting that its stock price is 48% more volatile than the broader market.

Sana Biotechnology currently has a consensus price target of $9.50, indicating a potential upside of 206.95%. Protara Therapeutics has a consensus price target of $26.25, indicating a potential upside of 572.90%. Given Protara Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Protara Therapeutics is more favorable than Sana Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sana Biotechnology	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67
Protara Therapeutics	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75

88.2% of Sana Biotechnology shares are owned by institutional investors. Comparatively, 38.1% of Protara Therapeutics shares are owned by institutional investors. 25.4% of Sana Biotechnology shares are owned by insiders. Comparatively, 7.6% of Protara Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, Sana Biotechnology had 4 more articles in the media than Protara Therapeutics. MarketBeat recorded 4 mentions for Sana Biotechnology and 0 mentions for Protara Therapeutics. Sana Biotechnology's average media sentiment score of 0.26 beat Protara Therapeutics' score of 0.00 indicating that Sana Biotechnology is being referred to more favorably in the media.

Company	Overall Sentiment
Sana Biotechnology	Neutral
Protara Therapeutics	Neutral

Summary

Sana Biotechnology and Protara Therapeutics tied by winning 6 of the 12 factors compared between the two stocks.

How does Protara Therapeutics compare to Theravance Biopharma?

Theravance Biopharma (NASDAQ:TBPH) and Protara Therapeutics (NASDAQ:TARA) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, risk, profitability, media sentiment, valuation, dividends, institutional ownership and analyst recommendations.

99.1% of Theravance Biopharma shares are owned by institutional investors. Comparatively, 38.1% of Protara Therapeutics shares are owned by institutional investors. 7.7% of Theravance Biopharma shares are owned by insiders. Comparatively, 7.6% of Protara Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Theravance Biopharma has a beta of 0.19, suggesting that its stock price is 81% less volatile than the broader market. Comparatively, Protara Therapeutics has a beta of 1.48, suggesting that its stock price is 48% more volatile than the broader market.

Theravance Biopharma currently has a consensus price target of $19.40, suggesting a potential upside of 15.03%. Protara Therapeutics has a consensus price target of $26.25, suggesting a potential upside of 572.90%. Given Protara Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Protara Therapeutics is more favorable than Theravance Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Theravance Biopharma	0 Sell rating(s)	8 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Protara Therapeutics	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75

Theravance Biopharma has a net margin of 104.34% compared to Protara Therapeutics' net margin of 0.00%. Theravance Biopharma's return on equity of 18.84% beat Protara Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Theravance Biopharma	104.34%	18.84%	10.94%
Protara Therapeutics	N/A	-38.70%	-36.02%

Theravance Biopharma has higher revenue and earnings than Protara Therapeutics. Protara Therapeutics is trading at a lower price-to-earnings ratio than Theravance Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Theravance Biopharma	$107.46M	8.09	$105.89M	$2.20	7.67
Protara Therapeutics	N/A	N/A	-$57.44M	-$1.34	N/A

In the previous week, Theravance Biopharma had 3 more articles in the media than Protara Therapeutics. MarketBeat recorded 3 mentions for Theravance Biopharma and 0 mentions for Protara Therapeutics. Theravance Biopharma's average media sentiment score of 1.61 beat Protara Therapeutics' score of 0.00 indicating that Theravance Biopharma is being referred to more favorably in the media.

Company	Overall Sentiment
Theravance Biopharma	Very Positive
Protara Therapeutics	Neutral

Summary

Theravance Biopharma beats Protara Therapeutics on 11 of the 15 factors compared between the two stocks.

How does Protara Therapeutics compare to Arbutus Biopharma?

Protara Therapeutics (NASDAQ:TARA) and Arbutus Biopharma (NASDAQ:ABUS) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, risk, analyst recommendations, media sentiment, profitability, valuation and dividends.

Protara Therapeutics currently has a consensus target price of $26.25, indicating a potential upside of 572.90%. Arbutus Biopharma has a consensus target price of $5.00, indicating a potential upside of 14.29%. Given Protara Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Protara Therapeutics is more favorable than Arbutus Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Protara Therapeutics	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75
Arbutus Biopharma	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

38.1% of Protara Therapeutics shares are held by institutional investors. Comparatively, 43.8% of Arbutus Biopharma shares are held by institutional investors. 7.6% of Protara Therapeutics shares are held by insiders. Comparatively, 19.9% of Arbutus Biopharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Arbutus Biopharma has higher revenue and earnings than Protara Therapeutics. Protara Therapeutics is trading at a lower price-to-earnings ratio than Arbutus Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Protara Therapeutics	N/A	N/A	-$57.44M	-$1.34	N/A
Arbutus Biopharma	$191.45M	4.51	-$33.50M	$0.83	5.27

Arbutus Biopharma has a net margin of 83.95% compared to Protara Therapeutics' net margin of 0.00%. Arbutus Biopharma's return on equity of 129.32% beat Protara Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Protara Therapeutics	N/A	-38.70%	-36.02%
Arbutus Biopharma	83.95%	129.32%	112.24%

In the previous week, Arbutus Biopharma had 3 more articles in the media than Protara Therapeutics. MarketBeat recorded 3 mentions for Arbutus Biopharma and 0 mentions for Protara Therapeutics. Arbutus Biopharma's average media sentiment score of 1.19 beat Protara Therapeutics' score of 0.00 indicating that Arbutus Biopharma is being referred to more favorably in the news media.

Company	Overall Sentiment
Protara Therapeutics	Neutral
Arbutus Biopharma	Positive

Protara Therapeutics has a beta of 1.48, suggesting that its share price is 48% more volatile than the broader market. Comparatively, Arbutus Biopharma has a beta of 0.62, suggesting that its share price is 38% less volatile than the broader market.

Summary

Arbutus Biopharma beats Protara Therapeutics on 11 of the 15 factors compared between the two stocks.

Get Protara Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TARA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TARA vs. The Competition

Export

Metric	Protara Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$218.07M	$3.51B	$6.81B	$12.55B
Dividend Yield	N/A	3.78%	2.59%	10.03%
P/E Ratio	-2.90	7.39	282.12	24.83
Price / Sales	N/A	1,209.27	573.08	78.59
Price / Cash	N/A	44.80	28.60	46.71
Price / Book	1.03	16.98	11.02	6.15
Net Income	-$57.44M	-$12.56M	$3.49B	$347.61M
7 Day Performance	-3.44%	-1.85%	0.47%	1.17%
1 Month Performance	-3.92%	-8.52%	-4.24%	-3.46%
1 Year Performance	27.48%	47.51%	62.63%	19.43%

Protara Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TARA Protara Therapeutics	1.8482 of 5 stars	$3.95 +0.7%	$26.25 +564.7%	+28.1%	$221.95M	N/A	N/A	30	Positive News
PURR Hyperliquid Strategies	1.9742 of 5 stars	$6.34 +2.4%	$12.72 +100.6%	N/A	$894.13M	$1M	N/A	N/A	Gap Up
PHAR Pharming Group	2.7518 of 5 stars	$12.76 +1.1%	$38.33 +200.5%	-8.0%	$892.87M	$376.13M	79.72	280	News Coverage Earnings Report Analyst Revision
SANA Sana Biotechnology	2.106 of 5 stars	$3.28 +3.1%	$9.50 +189.6%	-19.9%	$884.97M	N/A	N/A	380	Upcoming Earnings Gap Up
TBPH Theravance Biopharma	2.7485 of 5 stars	$16.86 flat	$19.40 +15.1%	+54.7%	$869.18M	$107.46M	7.66	110	News Coverage Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TARA) was last updated on 8/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Protara Therapeutics (TARA) Competitors

TARA vs. PURR, PHAR, SANA, TBPH, and ABUS

How does Protara Therapeutics compare to Hyperliquid Strategies?

Summary

How does Protara Therapeutics compare to Pharming Group?

Summary

How does Protara Therapeutics compare to Sana Biotechnology?

Summary

How does Protara Therapeutics compare to Theravance Biopharma?

Summary

How does Protara Therapeutics compare to Arbutus Biopharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TARA vs. The Competition

Protara Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Protara Therapeutics (TARA) Competitors

TARA vs. PURR, PHAR, SANA, TBPH, and ABUS

How does Protara Therapeutics compare to Hyperliquid Strategies?

Do analysts rate PURR or TARA?

Do insiders and institutionals have more ownership in PURR or TARA?

Is PURR or TARA more profitable?

Which has more volatility & risk, PURR or TARA?

Which has better valuation & earnings, PURR or TARA?

Does the media favor PURR or TARA?

Summary

How does Protara Therapeutics compare to Pharming Group?

Do analysts prefer TARA or PHAR?

Is TARA or PHAR more profitable?

Which has higher valuation and earnings, TARA or PHAR?

Does the media favor TARA or PHAR?

Which has more risk and volatility, TARA or PHAR?

Do insiders & institutionals have more ownership in TARA or PHAR?

Summary

How does Protara Therapeutics compare to Sana Biotechnology?

Which has preferable earnings & valuation, SANA or TARA?

Is SANA or TARA more profitable?

Which has more risk & volatility, SANA or TARA?

Do analysts recommend SANA or TARA?

Do institutionals and insiders believe in SANA or TARA?

Does the media refer more to SANA or TARA?

Summary

How does Protara Therapeutics compare to Theravance Biopharma?

Do institutionals & insiders hold more shares of TBPH or TARA?

Which has more risk & volatility, TBPH or TARA?

Do analysts prefer TBPH or TARA?

Is TBPH or TARA more profitable?

Which has better earnings and valuation, TBPH or TARA?

Does the media prefer TBPH or TARA?

Summary

How does Protara Therapeutics compare to Arbutus Biopharma?

Do analysts rate TARA or ABUS?

Do insiders and institutionals have more ownership in TARA or ABUS?

Which has preferable valuation & earnings, TARA or ABUS?

Is TARA or ABUS more profitable?

Does the media prefer TARA or ABUS?

Which has more risk and volatility, TARA or ABUS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TARA vs. The Competition

Protara Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools